# Louise Emmett

Source: https://nuclide.cc/people/louise-emmett/  
Nuclide record `louise-emmett` (Person). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

Nuclear medicine physician who leads ENZA-p and the PSMA imaging trials shaping Australian theranostics.

## Summary

Louise Emmett (St Vincent's Hospital, Sydney) was principal investigator of ENZA-p, the ANZUP trial showing that adding 177Lu-PSMA-617 to enzalutamide delays progression in castration-resistant prostate cancer, and led the PRIMARY study of PSMA PET for diagnosis. She co-leads the ANZUP theranostics programme and writes widely used guidance on PSMA PET reporting.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: prostate; radioligand; australia
- Role: Director of Theranostics and Nuclear Medicine, St Vincent's Hospital Sydney; Professor, UNSW
- Specialisms: PSMA theranostics; Nuclear medicine; Prostate cancer imaging; Radioligand trials

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Emmett%20L%5BAuthor%5D%20PSMA

## Connected records

- isotopes: [Lutetium-177](https://nuclide.cc/isotopes/lu-177/)
- indications: [Prostate cancer](https://nuclide.cc/indications/prostate/)
- technologies: [PSMA PET](https://nuclide.cc/technologies/psma-pet/), [Radioligand therapy (beta emitters)](https://nuclide.cc/technologies/radioligand-therapy/)
- targets: [PSMA](https://nuclide.cc/targets/psma/)
- drugs: [Lutetium-177 vipivotide tetraxetan](https://nuclide.cc/drugs/pluvicto/)
- journals: [European Urology](https://nuclide.cc/journals/european-urology/)
- pairings: [177Lu-PSMA-617 (Pluvicto) with olaparib](https://nuclide.cc/pairings/pluvicto-plus-olaparib/)
- key papers: [TheraP: [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer](https://nuclide.cc/key-papers/paper-therap-lancet-2021/)

---
JSON: https://nuclide.cc/api/v1/entities/louise-emmett.json